7,8-Dihydroxyflavone is widely studied for its neuroprotective properties due to its ability to activate the TrkB receptor, which is the primary receptor for brain-derived neurotrophic factor (BDNF). This activation supports neuron survival, growth, and synaptic plasticity, making it a promising candidate in the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease. It has shown potential in improving cognitive function and memory in animal models. The compound also exhibits antidepressant-like effects in preclinical studies, suggesting utility in mood disorder therapies. Additionally, 7,8-Dihydroxyflavone has antioxidant and anti-inflammatory activities, which contribute to its protective effects in neuronal and other cell types. In research settings, it is used as a pharmacological tool to study BDNF signaling pathways without the limitations associated with using BDNF protein directly, such as poor blood-brain barrier penetration. Its small molecular size allows better bioavailability and central nervous system access, enhancing its experimental and therapeutic value.